Sobi publishes 2017 Annual and Sustainability Report
Marking World Haemophilia Day: over 260 million IUs of clotting factor donated by Sobi and Bioverativ during the last two years for WFH Humanitarian Aid
Swedish Orphan Biovitrum AB (publ) (Sobi™) publishes its 2017 Annual and Sustainability Report today on World Haemophilia Day. The report summarises our business and financial highlights for 2017 as well as our enhanced sustainability initiative.
“We have successfully launched our next-generation haemophilia products Elocta and Alprolix, and established a good position for them both in our main markets,” says Guido Oelkers, CEO and President. “Our track record of very strong quarter-on-quarter growth shows that we have managed to deliver consistently on our launch strategy. In the Annual Report, we have outlined how this growth will fuel our strategy to become global leaders in rare diseases, building on our capabilities and strengths within the field.”
Sobi is convinced that true availability and access to treatment for patients is what brings long-term value to the patients we serve, our employees, partners and shareholders. Today, on World Haemophilia Day, we take the opportunity to highlight one of our sustainability initiatives that we share with our partner Bioverativ, a Sanofi company.
In 2014, Sobi and Bioverativ, a Sanofi company, pledged to donate up to one billion international units (IUs) of clotting factor over 10 years, including up to 500 million IUs over a period of up to five years for the World Federation of Hemophilia’s WFH Humanitarian Aid Program, to help transform the way haemophilia care is delivered in the developing world. Since donations began in 2015, more than 15,000 people with haemophilia in 40 countries have already been treated with over 260 million IUs of medicine donated by Sobi and Bioverativ to the WFH Humanitarian Aid Program. The initiative has already had a significant impact including:
- Nearly tripling the percentage of children receiving treatment from 14 per cent to 39 per cent of patients treated
- Providing prophylactic treatment to around 1,200 people, two-thirds of whom are children under the age of 10
- Treating approximately 79,500 acute bleeds
- Enabling more than 1,500 surgeries, including life- and limb-saving operations.
“Sobi’s commitment to the WFH Humanitarian Aid Program is about making a real difference with our donations, and demonstrating a true long-term commitment to the haemophilia community and patients”, says Guido Oelkers.
The Sobi 2017 Annual and Sustainability Report is available in print, as a downloable pdf as well as an on-line version from our website sobi.com.
Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing innovative treatments that transform life for individuals with rare diseases.
The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.
For more information please contact
|Media relations||Investor relations|
|Linda Holmström, Senior Communications Manager||Jörgen Winroth, Vice President, Head of Investor Relations|
|+46 708 734 095||+1 347 224 0819, +1 212 579 0506|
Guido Oelkers, CEO Our track record of very strong quarter-on-quarter growth shows that we have managed to deliver consistently on our launch strategy